Recent research suggests that a new approach could help even patients with advanced forms of fatty liver disease.

Researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

The recipient, a liver cirrhosis patient who has been recuperating well since the Jan 20 transplant, went back home on Monday in good health. When the doctors embarked on the transplant ...

Can-Fite BioPharma (CANF) announced a significant clinical development: the disappearance of episodes of decompensated liver cirrhosis ...

Innovative therapies and surgical techniques have the potential to transform liver cancer care. People with cirrhosis—a ...

Discover why combining simvastatin and rifaximin does not offer a clinically meaningful advantage in preventing severe ...

an advanced stage of cirrhosis often associated with liver failure, currently has no approved therapeutic options other than liver transplantation. At 20 months into treatment, the patient reports ...

Metabolic dysfunction-associated steatohepatitis (MASH) significantly increases the risk of liver cirrhosis and ...

and establish whether HMB can indeed deliver real benefits for people with cirrhosis and those around them." Those leading the project also held meetings with patients diagnosed with liver ...

(RTTNews) - Can-Fite BioPharma Ltd. (CANF), announced on Tuesday that a patient experienced the disappearance of episodes of decompensated liver cirrhosis following treatment with Namodenoson ...

However, where it fell short was with respect to the failure at week 36 with the phase 2b SYMMETRY study, which used EFX to treat compensated cirrhosis patients ... 3 SYNCHRONY Real-World study ...

Akero's 50mg EFX led to a 24% effect size for cirrhosis reversal ... including real-time stock ratings, insider trades, and government trading signals. Among patients with baseline and week ...